Botanix Pharmaceuticals Limited (BOT.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 03:57PM AEDT
Loading interactive chart…
- Simply Wall St.
We're A Little Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Simply Wall St.
The past three years for Botanix Pharmaceuticals (ASX:BOT) investors has not been profitable
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So spare a...
- GlobeNewswire
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developin
© 2023 Yahoo. All rights reserved.
